Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Active, not recruiting · Phase 2 · NCT02940301
Conditions: Classical Hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $193,517
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Tested
- Ibrutinib (drug), Laboratory Biomarker Analysis (other), Nivolumab (biological)
- Dates
- Started 2016-12-20; completion 2027-02-15
- Results posted
- Not yet
This phase II trial studies how well ibrutinib and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back or has not responded to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells. Giving ibrutinib and nivolumab may work better in treating patients with classical Hodgkin lymphoma.
From ClinicalTrials.gov, last updated 2026-09-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $193,517 in research payments for this study in 2025 (3 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.